Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia
December 15 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Francesco Bandello,
MD, FEBO, Professor and Chairman of the Department of
Ophthalmology, University Vita-Salute, Ospedale San Raffaele,
Milan, will present pivotal safety and efficacy data from Outlook
Therapeutics’ Phase 3 NORSE TWO registration trial for ONS-5010 /
LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic
formulation of bevacizumab for use in wet age-related macular
degeneration (wet AMD). The presentation will take place at the 9th
International Congress on OCT and OCT Angiography in Rome (ICOOR)/
FLORetina Symposia, on Saturday, December 18, 2021.
“The results observed for ONS-5010 in the NORSE
TWO trial are potentially of great significance for retinal
specialists and their patients suffering from wet AMD,” said Dr.
Bandello. “I look forward to having an additional approved
treatment option for patients that is on-label and specifically
formulated and packaged to meet the stringent demands for
ophthalmic use.”
Details for Dr. Bandello’s presentation are as
follows:
Clinical and Efficacy Outcomes of the
NORSE TWO Pivotal Study for ONS-5010, an Ophthalmic Formulation of
BevacizumabPresenter: Francesco Bandello, MD, FEBOSession:
ICOOR 2021 Hall, Visions of Future by Industry and Engineers, Part
2Date and time: Saturday, December 18, 2021, 5:48 AM – 5:54 AM
Eastern Time (11:48 AM– 11:54 AM Central European Time)
For more information and to register for this
event, please visit ICOOR 2021.
About ICOOR and FLORetina
The International Congress on OCT and OCT
Angiography in Rome (ICOOR) and the FLORetina Symposia are
conducted under the auspices of AP Meetings. For almost 15 years,
AP Meetings has catered to the scientific and medical communities
and to surgical and pharmaceutical companies, organizing meetings
with single and multiple sponsors, congresses, conventions,
conferences, master courses of international and national
importance. AP Meetings provides CME (Continuing Medical Education)
and accreditation services for professional residential training
and retraining and CPD (online) for healthcare (medical and
para-medical). ICOOR/ FLORetina provides an international forum for
significant scientific presentations in the field of
ophthalmology.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024